Floatz logo

Cudc-907

NUT Midline Carcinoma

Curis, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the NUT Midline Carcinoma cohort.

Asset / SponsorPhaseRating
Bet Bromodomain Inhibitor Zen-3694
National Cancer Institute (NCI)
Phase 1CC
Molibresib
GlaxoSmithKline
Phase 1CC
Abemaciclib
National Cancer Institute (NCI)
Phase 1CC
ep31670
Epigenetix, Inc.
Phase 1CC
otx015
Merck Sharp & Dohme LLC
Phase 1C
mt-4561
Tanabe Pharma America, Inc.
Phase 1/2NR

Same molecule, other indications

Cudc-907 is also rated in:

ovarian serous adenocarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
neuroblastomaDormant
CC
Indicative ·
44 / 100
View asset →
brain neoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →